olmesartan medoxomil (Votum)

Subscribe to Selected New Research on olmesartan medoxomil

82 relevant articles (26 outcomes, 33 trials/studies) found for this Drug

Description: angiotensin II receptor antagonist; structure in first source

Also Known As:

Votum; Benicar; Olmetec; (5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxy-4-(1-hydroxy-1-methylethyl)-2-propyl-1-(4-(2-(tetrazol-5-yl)phenyl)phenyl)methylimidazol-5-carboxylate; Berlin-Chemie Brand of Olmesartan Medoxomil; CS 866; CS-866; Forest Brand of Olmesartan Medoxomil; Sankyo Brand of Olmesartan Medoxomil

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 23

1-Ring Heterocyclic Compounds

Azoles: 224

Imidazoles: 94

olmesartan medoxomil: 82

Tetrazoles: 5

olmesartan medoxomil: 82

Experts

1.	Barrios, Vivencio: 2 articles (01/2008 - 01/2007)
2.	Heagerty, Anthony: 2 articles (10/2007 - 01/2007)
3.	Chrysant, S G: 2 articles (09/2007 - 06/2003)
4.	Giles, Thomas D: 2 articles (03/2007 - 08/2004)
5.	Böhm, Michael: 2 articles (01/2007 - 01/2004)
6.	Neutel, Joel M: 2 articles (04/2004 - 01/2004)
7.	Karki, Sulekha: 1 article (04/2008)
8.	Heyrman, Reinilde: 1 article (04/2008)
9.	Lee, James: 1 article (04/2008)
10.	Chrysant, Steven G: 1 article (04/2008)

Related Diseases

1.	Hypertension (High Blood Pressure) 06/01/2001 - "CONCLUSIONS: Olmesartan medoxomil was safe and highly effective in lowering blood pressure in patients with mild to moderate essential hypertension in these studies." 01/01/2007 - "In an integrated analysis of seven US and European randomized, placebo-controlled, dose-ranging trials involving 3055 patients with stage 2 hypertension treated with olmesartan medoxomil 2.5-80 mg/day or placebo for 8 weeks, all olmesartan medoxomil doses were significantly more effective than placebo in lowering the mean DBP and mean SBP (p<or=0.001); notably, optimal BP-lowering efficacy was observed at higher dosages" 10/01/2004 - "These facts suggest that olmesartan medoxomil would be beneficial for the treatment of hypertension and other end-organ diseases." 04/01/2003 - "RESULTS: Olmesartan medoxomil has been reported to be an effective agent for the treatment of hypertension" 09/01/2002 - "Olmesartan medoxomil appears to be a safe and effective once-a-day treatment for hypertension." Get all the results and reference details, order at left...
2.	Atherosclerosis (Atheroma) 01/01/2006 - "The efficacy of olmesartan medoxomil in reducing cardiovascular risk beyond BP reduction is currently being investigated in trials involving patients at high risk due to atherosclerosis or type 2 diabetes." 01/01/2006 - "Effect of olmesartan medoxomil on atherosclerosis: clinical implications of the emerging evidence." 04/19/2001 - "CS-866 was also tested in the Watanabe heritable hyperlipidemic (WHHL) rabbit model of atherosclerosis" 01/01/2003 - "Additionally, animal studies indicate that olmesartan medoxomil may prove to be useful treatment for diabetic nephropathy, as well as atherosclerosis" 04/19/2001 - "On the basis of results from animal models, CS-866 may be a useful treatment for diabetic nephropathy and atherosclerosis." Get all the results and reference details, order at left...
3.	Diabetic Nephropathies (Diabetic Nephropathy) 01/01/2005 - "Our study suggests that olmesartan medoxomil could be a valuable drug for the treatment of diabetic nephropathy by blocking the deleterious effects of AGEs." 10/01/2002 - "In electron microscopic analysis, loss of glomerular anionic sites, one of the causes of glomerular hyperpermeability in diabetic nephropathy, was found to be significantly prevented by CS-866 treatment" 01/01/2003 - "Additionally, animal studies indicate that olmesartan medoxomil may prove to be useful treatment for diabetic nephropathy, as well as atherosclerosis" 04/19/2001 - "On the basis of results from animal models, CS-866 may be a useful treatment for diabetic nephropathy and atherosclerosis." 04/19/2001 - "Given the proposed involvement of the renin-angiotensin system in diabetic nephropathy and atherosclerosis, we have tested CS-866 in animal models of these conditions" Get all the results and reference details, order at left...
4.	Insulin Resistance 07/07/2008 - "We evaluated the role of the renin-angiotensin system in the pathogenesis of insulin resistance-associated, non-alcoholic steatohepatitis by using the angiotensin II type 1 receptor blocker olmesartan medoxomil in a diabetic rat model" 04/01/2004 - "Olmesartan medoxomil, an angiotensin II receptor blocker ameliorates insulin resistance and decreases triglyceride production in fructose-fed rats." 11/01/2000 - "Temocapril and CS-866 lowered systolic blood pressure, improved insulin resistance, and reduced TNF-alpha in both skeletal muscles" 04/01/2004 - "In this study we addressed this issue by investigating how a newly developed ARB, olmesartan medoxomil, influenced insulin sensitivity and TG metabolism in fructose-fed rats, a representative animal model of insulin resistance" Get all the results and reference details, order at left...
5.	Pulmonary Heart Disease (Cor Pulmonale) 12/28/2005 - "The present study clearly indicates that the angiotensin II-type I-receptor blocker olmesartan medoxomil has significant efficacy for hypoxic cor pulmonale." 12/28/2005 - "Olmesartan medoxomil significantly reduced the induction of hypoxic cor pulmonale not only on echocardiographical observations but also in BNP, TGF-beta and endothelin gene expressions in molecular studies" Get all the results and reference details, order at left...
43 Diseases and 82 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Angiotensin Receptors (Angiotensin II Receptor)
2.	Amlodipine (Norvasc)
3.	Hydrochlorothiazide (Esidrix)
4.	Angiotensin II
5.	Losartan (Cozaar)
6.	temocapril hydrochloride (temocapril)
7.	olmesartan
8.	irbesartan
9.	Transforming Growth Factor beta (TGF-beta)
10.	telmisartan (Micardis)
505 Drugs and Important Bio-Agents and 64 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Sodium-Restricted Diet (Diet, Sodium Restricted)
2.	Peritoneal Dialysis
3.	Stents
4.	Aftercare (After-Treatment)
4 Therapies and Procedures and 6 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>